Hepatology International

Article	Citations
Gut microbiota alteration in hepatobiliary diseases: cause-and-effect relationship	120
Abstract	93
Is laparoscopic liver resection more suitable for diabetic patients with hepatocellular carcinoma? The debate continues	83
Obituary	75
Correction: Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group	71
New progress towards elimination of mother-to-child transmission of hepatitis B virus in China	63
Delicate and thin fibrous septa indicate a regression tendency in metabolic dysfunction-associated steatohepatitis patients with advanced fibrosis	63
Could the TAE score predicting the prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors be better if certain revisions are made?	54
Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma	54
Transjugular intrahepatic collateral-systemic shunt is effective for cavernous transformation of the portal vein with variceal bleeding	52
A preoperative scoring system to predict lymph node metastasis in intrahepatic cholangiocarcinoma	52
Consensus on the secondary prevention of primary liver cancer	51
Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines	48
Correction to: Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells	47
Correction to: Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure	46
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network	46
Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma	41
PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study	40
Alcohol-related hepatitis admissions decline in 2021 after a 2020 surge attributed to the COVID-19 pandemic	40
Evaluation of the histologic and immunohistochemical (CD34, glutamine synthetase) findings in idiopathic non-cirrhotic portal hypertension (INCPH)	39
Incidence, risk factors, and outcomes of acute liver injury in hospitalized adults with acute kidney injury: a large multicenter study	38
Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated	38
Reconsiderations for the liver donation from a living donor: addressing hepatic steatosis with weight loss preconditioning	37
Metabolically healthy obese and MAFLD: does weight status alone matter?	37
Development of a transformer model for predicting the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation	34

Dairy products intake and prevalence, incidence, and recovery of non-alcoholic fatty liver disease in Chinese population	32
Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study	32
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	32
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	32
Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier	32
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry	32
Evolution of risk prediction models for post-operative mortality in patients with cirrhosis	30
Treating extrahepatic portal-vein obstruction with cavernoma using radiological interventions: pushing the boundaries	29
Targeted APT8(16–34) obtained by cell-SELEX and its internalization with miR-23-5p into activated hepatic stellate cells	29
Reciprocal alterations in circulating and hepatic gamma–delta T cells in patients with primary biliary cholangitis	29
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	27
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions: Correspondence	27
PIRO-CIC model can predict mortality and futility of care in critically ill cirrhosis patients in the intensive care unit	27
A multicenter propensity score analysis of significance of hepatic resection type for early-stage hepatocellular carcinoma	26
The safety profile of endoscopic variceal ligation in patients with esophageal varices	26
Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis	26
Hepatitis B virus-related intrahepatic cholangiocarcinoma originates from hepatocytes	26
Comments on: Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis	25
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)	25
Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan	25
Prognosis prediction or treatment allocation?	25
Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma	25
Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle	25
Planning, implementing, and evaluating Hepatitis C virus elimination via collaborative community-based care cascade: age–period–cohort model for estimating demand from antecedent anti-HCV survey	24
Hepatic fibrosis is associated with an increased rate of decline in bone mineral density in men with nonalcoholic fatty liver disease	24
Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma	24
MAFLD: from a disease framework to patient care	23
Platelets in acute liver failure: an innocent bystander or instigator?	23
Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis	23
The clinical implications of pre-liver transplant diabetes on post-liver transplant outcomes in patients with NASH: analysis of the UNOS database	23
Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study	22
Acute-on-chronic liver failure (ACLF): the ‘Kyoto Consensus’—steps from Asia	22
Oxidative stress triggers hyperdynamic circulation via central neural activation in portal hypertensive rats	22
Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications	22
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence	22
Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study	21
Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives	21
Hepatocellular carcinoma (HCC) tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) tumor microenvironment	21
MAFLD but not MASLD increases risk of all-cause mortality in regional Australia, with components of metabolic syndrome exacerbating factors: 20 year longitudinal, cohort study	21
Diagnosis and management of pediatric acute liver failure: consensus recommendations of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN)	21
Longitudinal progression of clinical variables associated with graded liver injury in COVID-19 patients	21
Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial	21
DENND3 p.L708V activating variant is involved in the pathogenesis of hereditary hemochromatosis via the RAB12/TFR2 signaling pathway	20
Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective	20
The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion	20
Artificial intelligence in liver imaging: methods and applications	20
‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure	20
Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)	19
Response to: Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial	19
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease	19

TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial	19
Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial	19
FXR overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in alcoholic liver disease	19
Post-transplant inflammatory cytokine signature adds value for predicting tumor recurrence after liver transplantation for hepatocellular carcinoma	19
Global, regional, and national temporal trends in incidence and mortality for liver cancer due to hepatitis B, 1990–2021: a decomposition and age-period-cohort analysis for the Global Burden of Diseas	18
Countdown on hepatitis B elimination by 2030: the global burden of liver disease related to hepatitis B and association with socioeconomic status	18
Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait	18
Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma	18
Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study	18
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion	17
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”	17
Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population	17
Abstracts	17
Chinese expert consensus on clinical management of hepatopathy-related thrombocytopenia (2023 edition)	17
MAFLD identifies patients with significant hepatic fibrosis better than MASLD	17
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies	17
Deep learning and non-invasive assessment of significant fibrosis: does adding more toppings improve the flavor of prediction?	17
Impact of chronic hepatitis B and concurrent steatosis on the risk of hepatocellular carcinoma	16
Patterns and outcomes of early and late recurrence after hepatectomy for hepatocellular carcinoma with microvascular invasion: a multicenter study in China	16
Telomere length and mortality in lean MAFLD: the other face of metabolic adaptation	16
G-CSF treatment in decompensated liver disease: a double-edged sword?	16
Correction to: The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study	16
Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis	16
NAFLD and MAFLD independently increase the risk of major adverse cardiovascular events (MACE): a 20-year longitudinal follow-up study from regional Australia	16
Low platelets: a new and simple prognostic marker for patients with hepatitis E virus-related acute liver failure	16
Non-canonical Wnt signaling pathway activated NFATC3 promotes GDF15 expression in MASH: prospective analyses of UK biobank proteomic data	16
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment	15
Prophylaxis of hepatic encephalopathy: current and future drug targets	15
The regulation effect of GLUT9/SLC2A9 on intrahepatic uric acid level and metabolic associated fatty liver disease	15
Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019	15
Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues	15
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection	15
Impact of elobixibat on liver tumors, microbiome, and bile acid levels in a mouse model of nonalcoholic steatohepatitis	15
Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular–cholangiocarcinoma	14
Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria	14
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis	14
Correction to: Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study	14
Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies	14
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis	14
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5	14
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma	13
Is laparoscopic hepatectomy superior to radiofrequency ablation in treating small hepatocellular carcinoma?	13
Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks	13
Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants	13
Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States	13
Editorial: The safety profile of endoscopic variceal ligation in patients with esophageal varices. Authors’ reply	13
Clinical characteristics and managements of congenital hepatic hemangioma: a cohort study of 211 cases	13
The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy	13
Targeting ferroptosis in hepatocellular carcinoma	13
Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group	13
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality	13
Validation of Baveno VII criteria for clinically significant portal hypertension by two-dimensional shear wave elastography	13
Chinese guidelines on the management of ascites in cirrhosis	12
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes	12
miR-98-5p as a novel biomarker suppress liver fibrosis by targeting TGFβ receptor 1	12
Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury	12
“Cherry blossom” in Kyoto brought hope to patients with chronic hepatitis B infection	12
Pre-hepatectomy dynamic circulating tumor DNA to predict pathologic response to preoperative chemotherapy and post-hepatectomy recurrence in patients with colorectal liver metastases	12
Who better identifies significant liver fibrosis, MAFLD or MASLD, needs more rigorous, in-depth study	12
Prevalence and clinical significance of serum sodium variability in patients with acute-on-chronic liver diseases: a prospective multicenter study in China	11
Two-year risedronate treatment for osteoporosis in patients with esophageal varices: a non-randomized clinical trial	11
Tenofovir Alafenamide use in pregnant women with chronic hepatitis B virus infection: more data needed	11
Nomograms should be noted	11
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis	11
OHCCPredictor: an online risk stratification model for predicting survival duration of older patients with hepatocellular carcinoma	11
Hyperdynamic circulation in cirrhosis: a novel gutsy central neuronal mechanism	11
Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma	11
SARS-CoV-2 infection and liver involvement	11
Predictive power of portal pressure gradient remeasured shortly after transjugular intrahepatic portosystemic shunt	11
Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease	11
Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial	11
Carbohydrate-deficient transferrin is a sensitive marker of alcohol consumption in fatty liver disease	11
Healthcare utilization and outcomes of living donor liver transplantation for patients with APASL-defined acute-on-chronic liver failure	11
Clinical practice guidelines on hemochromatosis: Asian Pacific Association for the Study of the Liver	11
Perioperative and long-term survival outcomes of laparoscopic versus laparotomic hepatectomy for BCLC stages 0–A hepatocellular carcinoma patients associated with or without microvascular invasion: a	11
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India	11
Asia–Pacific association for study of liver guidelines on management of ascites in liver disease	11
Aspirin improves transplant-free survival after TIPS implantation in patients with refractory ascites: a retrospective multicentre cohort study	11
Global burden of cirrhosis and liver cancer due to alcohol: the past, present, and the future	11
Emergent rescue transjugular intrahepatic portosystemic shunt within 8 h improves survival in patients with refractory variceal bleed	10

“Dosis sola facit venenum”—Evidence for causality in the association between ketamine and cholestatic liver injury	10
The differences in post-liver transplant outcomes of patients with autoimmune hepatitis who present with overlapping autoimmune liver diseases	10
Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC)	10
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis	10
Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics	10
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease	10
Dynamic analysis of serum MMP-7 and its relationship with disease progression in biliary atresia: a multicenter prospective study	10
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	10
Biomarkers of endothelial dysfunction in alcoholic hepatitis	10
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	10
Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study	10
Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn’s disease but not Ulcerative Colitis: a prospective cohort study	10
A prognostic model for hepatocellular carcinoma patients based on signature ferroptosis-related genes	10
Contribution of alcohol use to the global burden of cirrhosis and liver cancer from 1990 to 2019 and projections to 2044	10
Gut-microbiome composition and function in progression of alcohol-associated liver disease: going beyond western experiences	10
Evidence of nucleos(t)ide analogue (NUC) therapy in HBV DNA negative decompensated cirrhosis	10
Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure	10
Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial	9
CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection	9
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy	9
Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease	9
Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial	9
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets	9
Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation	9
Metabolic dysfunction-associated fatty liver disease as a risk factor for adverse outcomes in subsequent pregnancy: a nationwide cohort study	9
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy	9
Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?	9
Assessment of liver fibrosis by transient elastography in young children with chronic hepatitis B virus infection	9
Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review	9
Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma	9
Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease	9
Influence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	9
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort	8
The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients	8
Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma	8
Hepatitis B: “Treat all” or “Treat select”	8
‘Hepatic tuberculosis: a sheep in wolf’s clothing’. Author response	8
Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers	8
Histology activity index: a benchmark for decision making	8
Immune checkpoint inhibitors in chronic hepatitis B: therapy or high-risk factor for reactivation?	8
miR-488-5p mitigates hepatic stellate cell activation and hepatic fibrosis via suppressing TET3 expression	8
TRIM28 functions as SUMO ligase to SUMOylate TRAF6 and regulate NF-κB activation in HBV-replicating cells	8
Radiomics analysis of contrast-enhanced CT for staging liver fibrosis: an update for image biomarker	8
APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients	8
Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection	8
Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease	8
The overview of the deep learning integrated into the medical imaging of liver: a review	8
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?	8
Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain	8
Hepatic tuberculosis: a sheep in wolf’s clothing	8
Predictive performance and clinical utility of HCC risk scores in chronic hepatitis C: a comparative study	8
Non-alcoholic fatty liver disease frequency and associated factors at admission of acute stroke	8
Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools	8
Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed	8
The contribution of genetics and epigenetics to MAFLD susceptibility	8
An international multidisciplinary consensus statement on MAFLD and the risk of CVD	8
Ending stigmatizing language in alcohol and liver disease: a liver societies’ statement	8
The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes	8
Higher inflammatory response in hepatocellular carcinoma is associated with immune cell infiltration and a better outcome	8
Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma	8
Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures	8
Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL	8
Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease	8
The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study	8
The clinical and economic burden of non-alcoholic steatohepatitis in the Middle East: behind the scene	8
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis	8
Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period	8
Hepatobiliary long-term consequences of COVID-19: dramatically increased rate of secondary sclerosing cholangitis in critically ill COVID-19 patients	7
Reply to: “developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond”	7
The relationship between CXCR6+CD8+T cells and clinicopathological parameters in patients with primary biliary cholangitis	7
Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kina	7
Response to the letter of HEPI-D-24–00252	7
Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure	7
Clinic-radiomics model using liver magnetic resonance imaging helps predict chronicity of drug-induced liver injury	7
Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis	7
Connection between HPS and ACLF: a solution of chaos?	7
Clinical characteristics and prognosis of non-APAP drug-induced acute liver failure: a large multicenter cohort study	7
Targeting immuno-metabolism and anti-viral immune responses in chronic hepatitis B	7
Genetic variants of NTCP gene and hepatitis B vaccine failure in Taiwanese children of hepatitis B e antigen positive mothers	7
Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury	7
Metabolic dysfunction associated fatty liver disease in healthy weight individuals	7
Gonadal dysfunction in male patients with Budd Chiari syndrome and its reversibility with treatment	7
MAFLD: perceived stigma—a single-center Mexican patient survey	7
The incidence of all organ malignancies and overall survival of patient with sustained virological response of HCV-comparable to SMR (standardized mortality ratio) of Japan general population	7
Reply to: The best predictive model for post-SVR HCC: can it be universal?	7
Clinical evaluation of droplet digital pcr for suspected ascites infection in patients with liver cirrhosis	7
Reflections on prediction of microvascular invasion in hepatocellular carcinoma by pathology images	7
How non-alcoholic fatty liver disease and cirrhosis affect the heart	7
Image-matching digital macro-slide—a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma	6
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial	6
A prognostic model of acute-on-chronic liver failure based on sarcopenia	6
Comments on: Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis	6
Automated fibrosis phenotyping of liver tissue from non-tumor lesions of patients with and without hepatocellular carcinoma after liver transplantation for non-alcoholic fatty liver disease	6
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma	6
Correction to: Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease	6